tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Seagen (SGEN) and Humanigen (HGEN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Seagen (SGENResearch Report) and Humanigen (HGENResearch Report).

Seagen (SGEN)

Berenberg Bank analyst Zhiqiang Shu maintained a Buy rating on Seagen today and set a price target of $180.00. The company’s shares closed last Tuesday at $176.64.

According to TipRanks.com, Shu has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -22.5% and a 24.4% success rate. Shu covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Monte Rosa Therapeutics, and Sensei Biotherapeutics.

Currently, the analyst consensus on Seagen is a Moderate Buy with an average price target of $177.69, implying a 2.0% upside from current levels. In a report issued on July 15, Morgan Stanley also maintained a Buy rating on the stock with a $180.00 price target.

See the top stocks recommended by analysts >>

Humanigen (HGEN)

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Hold rating on Humanigen. The company’s shares closed last Tuesday at $0.41, close to its 52-week low of $0.41.

According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -29.1% and a 21.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Bioline RX Ltd Sponsored ADR, and Applied Genetic Technologies.

Currently, the analyst consensus on Humanigen is a Hold with an average price target of $4.88, implying a 1001.6% upside from current levels. In a report issued on July 13, Cantor Fitzgerald also downgraded the stock to Hold with a $2.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SGEN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More